Clinical trials: Chemotherapy-induced Thrombocytopenia
Chemotherapy-induced Thrombocytopenia
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects with Gastrointestinal, Pancreatic, or Colorectal Cancer
- Trial name
- RECITE (NCT03362177)
- Testing
- Romiplostim
- Where
- 117 sites in United States, Argentina and 18 more
- Volunteers
- 165 people
- Sponsor
- Amgen
Chemotherapy-induced Thrombocytopenia
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer
To evaluate the efficacy of romiplostim for the treatment of CIT in patients receiving chemotherapy for the treatment of NSCLC, ovarian cancer, or breast cancer measured by the ability to administer on-time, full-dose chemotherapy
- Trial name
- NCT03937154
- Testing
- Romiplostim
- Where
- 34 sites in United States, Argentina and 8 more
- Volunteers
- 145 people
- Sponsor
- Amgen
Patients With Chemotherapy-Induced Thrombocytopenia
A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia (ExCIT)
The ExCIT study is being conducted to evaluate the efficacy, and safety of of Hetrombopag Olamine Tablets Vs Placebo in Patients with Chemotherapy-Induced Thrombocytopenia.
- Trial name
- NCT07286032
- Testing
- Hetrombopag Olamine
- Where
- 51 sites in United States, Bulgaria and 9 more
- Volunteers
- 150 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Hematopoietic Stem Cell Mobilization
Early Prophylactic rhTPO Administration for Thrombocytopenia Associated With EAP Regimen-Based Hematopoietic Stem Cell Mobilization
This is a multicenter, prospective, single-arm, phase II clinical study evaluating the early prophylactic use of recombinant human thrombopoietin (rhTPO) to prevent thrombocytopenia associated with the EAP regimen for…
- Conditions
- Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Hematopoietic Stem Cell Mobilization, Chemotherapy-Induced Thrombocytopenia
- Trial name
- NCT07848672
- Testing
- rhTPO prophylaxis plus EAP stem-cell mobilization
- Volunteers
- 70 people
- Sponsor
- The Affiliated People's Hospital of Ningbo University
Gastrointestinal Cancer, Gastrointestinal Neoplasms
Avatrombopag vs. Placebo for CIT in GI Malignancies
The purpose of this study is to compare the efficacy of two study drugs, Avatrobopag versus placebo, to treat persistent Chemotherapy-Induced Thrombocytopenia (CIT) in patients with gastrointestinal (GI) malignancies receiving…
- Conditions
- Gastrointestinal Cancer, Gastrointestinal Neoplasms, Chemotherapy-Induced Thrombocytopenia
- Trial name
- ACT-GI (NCT05772546)
- Testing
- Avatrombopag
- Where
- 4 sites in United States
- Volunteers
- 49 people
- Sponsor
- Hanny Al-Samkari, MD
Thrombocytopenia Chemotherapy Induced
Romiplostim N01 for Injection for Secondary Prophylaxis of CIT in Breast Cancer
This study aims to evaluate the efficacy and safety of Romiplostim N01 for Injection administered as secondary prophylaxis in breast cancer patients with chemotherapy-induced thrombocytopenia (CIT).
- Trial name
- NCT07771881
- Testing
- Romiplostim N01
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Fudan University
Breast Cancer Patients at High Risk of Chemotherapy-induced Thrombocytopenia (CTIT)
A Clinical Study on Prophylactic RespOnse To hEtrombopag for Secondary Prevention in Anti-Cancer Therapy-induced Thrombocytopeniae
This study is a prospective clinical study enrolling breast cancer patients at high risk of chemotherapy-induced thrombocytopenia (CTIT).
- Trial name
- PROTECT (NCT07647029)
- Testing
- Continuous Hetrombopag for 2 Cycles, Cyclic 14-day Hetrombopag for 2 Cycles
- Volunteers
- 126 people
- Sponsor
- Fudan University
Persistent Isolated Chemotherapy-Induced Thrombocytopenia, Chemotherapy-Induced Thrombocytopenia
Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gastrointestinal Solid Tumors
This is a prospective, randomized, open-label, active-controlled study to evaluate the efficacy and safety of Romiplostim N01 plus all-trans retinoic acid (ATRA) compared with Romiplostim N01 alone in adults with persistent…
- Conditions
- Persistent Isolated Chemotherapy-Induced Thrombocytopenia, Chemotherapy-Induced Thrombocytopenia, Gastrointestinal Neoplasms, Pancreatic Cancer
- Trial name
- N01-A-PICIT-GI (NCT07586813)
- Testing
- Romiplostim N01, All-trans retinoic acid
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Peking University People's Hospital
Persistent Isolated Chemotherapy-Induced Thrombocytopenia, Chemotherapy-Induced Thrombocytopenia
Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors
This is a prospective, randomized, open-label, active-controlled study to evaluate the efficacy and safety of Romiplostim N01 plus all-trans retinoic acid (ATRA) compared with Romiplostim N01 alone in adults with persistent…
- Conditions
- Persistent Isolated Chemotherapy-Induced Thrombocytopenia, Chemotherapy-Induced Thrombocytopenia, Gynecologic Cancers, Ovarian Cancer
- Trial name
- N01-A-PICIT-GT (NCT07586826)
- Testing
- Romiplostim N01, All-trans retinoic acid
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Peking University People's Hospital
Solid Tumors, Hematological Tumor
Romiplostim N01 for Chemotherapy-Induced Thrombocytopenia in Pediatric Cancer Patients
The goal of this clinical trial is to evaluate the efficacy and safety of romiplostim N01 in treating chemotherapy-induced thrombocytopenia (CIT) in children and adolescents/young adults (CAYA; aged 6-24 years) with hematologic…
- Conditions
- Solid Tumors, Hematological Tumor, Children, Adolescent
- Trial name
- NCT07043894
- Testing
- Romiplostim N01
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Chemotherapy-induced Thrombocytopenia (CIT) in Patients With Gastrointestinal Tumors
Efficacy and Safety of Hetrombopag in Preventing Chemotherapy-induced Thrombocytopenia in Gastrointestinal Tumors
This trial is a single-arm, prospective clinical study aimed at evaluating the efficacy and safety of hetrombopag in preventing chemotherapy-induced thrombocytopenia (CIT) in patients with gastrointestinal tumors.
- Trial name
- NCT07492693
- Testing
- Hetrombopag
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Changhai Hospital
Ewings Sarcoma, Chemotherapy Induced Thrombocytopenia
Single Arm Romiplostim to Prevent CIT
The goal of this clinical trial is to to assess the efficacy of romiplostim as a supportive care measure in patients with a new diagnosis of Ewing sarcoma receiving interval-compressed chemotherapy.
- Trial name
- NCT07048249
- Testing
- Romiplostim (AMG-531)
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Cancer, Cancer-related Problem/Condition
Home Monitoring of Complete Blood Count Performed by Patients - a Pilot Study on the Implementation Process in South Baltic Countries.
Introduction: The number of diagnosed cancers is systematically increasing every year. Cancer patients need to undergo regular blood tests to monitor safety and eligibility for treatment.
- Conditions
- Cancer, Cancer-related Problem/Condition, Chemotherapy, Chemotherapy-induced Neutropenia
- Trial name
- AMBeR eBlood (NCT06809101)
- Where
- 5 sites in Denmark, Germany and 1 more
- Volunteers
- 265 people
- Sponsor
- Pomeranian Medical University Szczecin
Chemotherapy Induced Thrombocytopenia
A Clinical Study on the Efficacy and Safety of Hetrombopag in the Treatment of Thrombocytopenia Induced by Gynecological Tumor Therapy
The study consists of five sequential periods: Screening (≤ 4 weeks) Correction phase Maintenance phase (first treatment cycle, Cycle 1) Observation phase (second treatment cycle, Cycle 2) Follow-up Eligible subjects are…
- Trial name
- NCT07408648
- Testing
- hetrombopag 7.5 mg orally once daily
- Volunteers
- 244 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
CTIT-Chemotherapy Induced Thrombocytopenia
TPO Combined With TPORA for Solid Tumors Effectiveness of cTit Above Degree II
This study was an open-label, controlled, single-center, prospective phase II trial. In this prospective, real-world study, consecutive patients meeting eligibility criteria will be enrolled and allocated to: Group A (Grade Ⅱ…
- Trial name
- NCT06769685
- Testing
- rhTPO, hypertrombopa
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Jinhua Central Hospital
Nasopharyngeal Carcinoma (NPC), CTIT-Chemotherapy Induced Thrombocytopenia
A Clinical Study of Hetrombopag for Prevention of Thrombocytopenia Induced by Gemcitabine Plus Cisplatin in the Treatment of Nasopharyngeal Carcinoma
This study is a single-arm, exploratory, self-controlled clinical trial for the prevention of thrombocytopenia induced by gemcitabine plus cisplatin in the treatment of nasopharyngeal carcinoma.
- Trial name
- NCT07252375
- Testing
- herombopag olamine tablets
- Volunteers
- 35 people
- Sponsor
- Fujian Cancer Hospital
CTIT-Chemotherapy Induced Thrombocytopenia, Breast Cancer
Hetrombopag for the Prevention of ADC-Induced Thrombocytopenia in Breast Cancer: An Exploratory, Dual-Cohort, Phase 2 Study
The title of this study is: A two-cohort, single-arm, exploratory Phase II clinical study on the primary/secondary prevention ADC drug of heltrombopag for thrombocytopenia caused by breast cancer.
- Trial name
- NCT07243418
- Testing
- herombopag olamine tablets
- Volunteers
- 72 people
- Sponsor
- Fujian Cancer Hospital
Solid Tumor Malignancies, Cancer, CTIT-Chemotherapy Induced Thrombocytopenia
A Multicenter, Open-label, Randomized Controlled Trial Evaluating the Efficacy and Safety of Romiplostim N01 in the Treatment of Thrombocytopenia Associated With Concurrent/Sequential Chemoradiotherapy and Chemotherapy Combined With/Without Immunotherapy in Solid Tumors
The purpose of this clinical trial is to evaluate the safety and efficacy of Romiplostim N01 in patients with solid tumors who are undergoing concurrent/sequential radiotherapy and chemotherapy（combined with/without…
- Conditions
- Solid Tumor Malignancies, Cancer, CTIT-Chemotherapy Induced Thrombocytopenia, Thrombocytopenia
- Trial name
- NCT07185893
- Testing
- Human Interleukin-11, Romiplostim N01
- Where
- China
- Volunteers
- 106 people
- Sponsor
- Jun wang
Chemotherapy-induced Thrombocytopenia (CIT)
A Clinical Trial Evaluating SCB-219M in in Chemotherapy-induced Thrombocytopenia (CIT)
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Immunogenicity, Preliminary Efficacy and Pharmacokinetics of SCB-219M in the patients with chemotherapy-induced thrombocytopenia (CIT)
- Trial name
- NCT05426369
- Testing
- Recombinant Human Tumor Necrosis Factor Receptor II -Fc-TPO Mimetic Peptide Fusion Protein
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Sichuan Clover Biopharmaceuticals, Inc.
Chemotherapy-induced Thrombocytopenia, Romiplostim N01
Romiplostim N01 for Chemotherapy-induced Thrombocytopenia
To evaluate the efficacy and safety of Romiplostim N01 to treat chemotherapy-induced thrombocytopenia in tumors
- Trial name
- NCT07063225
- Testing
- Romiplostim N01
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China